Accuray unveils TCW-backed recapitalization with $15 million equity infusion

The radiation therapy company also outlined debt-to-preferred conversion, covenant relief through December 31, 2027, board changes and non-binding technology partnerships aimed at accelerating innovation and improving operations.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.